M

Myriad Genetics
D

MYGN

13.490
USD
0.13
(0.97%)
Market Open
Volume
9,680
EPS
0
Div Yield
-
P/E
-11
Market Cap
1,226,699,724
OverviewSignalsIdeasNews
Related Instruments
    BDX
    BDX
    -1.800
    (-0.79%)
    226.010 USD
    D
    DGX
    -1.060
    (-0.69%)
    152.040 USD
    H
    HOLX
    0.290
    (0.40%)
    71.940 USD
    ILMN
    ILMN
    -1.570
    (-1.16%)
    134.360 USD
    L
    LH
    -2.240
    (-0.98%)
    226.420 USD
    TMO
    TMO
    -1.32
    (-0.25%)
    521.90 USD
    More
News

Title: Myriad Genetics

Sector: Healthcare
Industry: Diagnostics & Research
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarkerdiscovery and companion diagnostic services to pharma and biotech companies.